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SUMMARY
Dental treatment performed in patients receiving oral
anticoagulant drug therapy is becoming increasingly
common in dental offices.
The aim of oral anticoagulant therapy is to reduce
blood coagulability to an optimal therapeutic range within
which the patient is provided some degree of protection from
thromboembolic events. This is achieved at the cost of a
minor risk of haemorrhage.
Frequently raised questions concern the safety and
efficacy of the various anticoagulation regimens and their
accompanying thromboembolic and bleeding risks relative
to invasive dental procedures.
The aim of this literature review is to evaluate the
available evidence on the impact of anticoagulant
medications on dental treatment and highlight certain patient
management issues closely interrelated to various aspects of
dental treatment.
For that purpose literature search in the electronic
database of Medscape, Pubmed-Medline, Science Direct,
and EBSCO host, in the data base of Medical University
Plovdiv and specialised published books in general medicine
and dentistry was made.
A total of 33 publications between 1995 and 2013
were identified: 12 review articles, 11 randomized controlled
and non-randomised studies, 6 guidelines and practical
guides, 1 meta-analysis and 3 specialised books.
Key words: oral anticoagulants, venous or arterial
thromboembolism, bleeding risk, INR, oral surgery, tooth
extraction, fibrin sealing, local haemostasis.
INTRODUCTION
Four Millions Patients worldwide are taking
medications that alter haemostasis and decrease the risk for
thromboembolic events. Oral anticoagulant therapy is
prescribed for prophylaxis and treatment of pulmonary
embolism, venous thromboembolism and deep vein
thrombosis, including thromboprophylaxis for the prevention
of postoperative venous thromboembolism after orthopaedic
surgical procedures as hip fracture and prosthetic total hip
or knee joint replacement, thromboembolic complications
associated with atrial fibrillation and/or prosthetic
replacement of cardiac valves. [1, 2]
Management of these patients with forthcoming
dental surgical procedures has changed dramatically
nowadays, but there are still differences in the approaches
of general dentists, oral and maxillofacial surgeons.
Several protocols for such patients have been
proposed and can be summarised as: temporary
discontinuation or a reduction in dose of oral anticoagulants
to obtain a subtherapeutic international normalised ratio
(INR); replacement of oral anticoagulation with heparin or
low-molecular weight heparins or no change in the therapy.
[3]
The balance between reduction in the drug dose on
the one hand, and excessive bleeding during surgery in
therapeutically anticoagulated patients on the other, is major
problem, particularly with outpatient procedures.
However, the latest recommendations emphasise that
the risk of tromboembolic complications outweigh the risk
of bleeding and the latter in patients with therapeutic INR
is small. It has therefore been suggested that the dose of oral
anticoagulant should not be discontinued or changed.
None of these approaches is risk free for the patient,
and the surgeon must make a clinical judgment of the risk-
benefit ratio between management strategies and adverse
complications. [2]
Oral anticoagulant medications
The most frequently used medications for oral
anticoagulant therapy are:
1. Anticoagulants with indirect action (coumarin
derivatives)
1.1. Acenocoumarol
2 Acenocoumarol is a derivative of coumarin and is
vitamin K antagonist. He have role in synthesis of factors
²², V²², ²Õ, Õ. Peak of action with oral intake occurs 12 h
after administration. After discontinuation, the action persists
for 48 - 72 h.
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Indications: atrial fibrillation and mitral stenosis, or
a history of embolism; atrial fibrillation and age over 65age;
hypertension; diabetes or expressed left ventricular
hypertrophy; intramural thrombus of the heart after a heart
infarction or aneurysm of the anterior hart wall (3-6 months);
artificial heart valves, with a limited left ventricular function.
[4, 5]
1.2. Warfarin sodium
19 Warfarin is also coumarin derivate and affects the
extrinsic clotting pathway by preventing the reduction of
vitamin K into its active form. Its effectiveness in the patient
is measured by the INR. Depending on the reason for the
anticoagulation (cardiovascular thrombo-embolic risk), the
patient’s target INR therapeutic ranges will be different.
Patients with atrial fibrillation, DVT, or stroke have a target
INR of 2.0 to 3.0, whereas after undergoing cardiac valve
replacement surgery, patients have a target range of 2.5 to
3.5.  [4, 5, 6, 7]
2. Direct thrombin inhibitors
2.1. Dabigatran is a selective, reversible direct
thrombin inhibitor currently used in Europe and North
America for stroke prevention in nonvalvular AF and in
Europe for VTE prophylaxis in orthopedic patients.
Dabigatran etexilate’s has comparatively rapid onset
of action. It is able to provide stable anticoagulation at a
fixed dose without the need for routine laboratory
monitoring of INR and associated dosage adjustments. No
specific antidote or reversal agent exists to counter the
anticoagulant effect of dabigatran. However, owing to
dabigatran’s short half-life (12-14 hours (14-17 hours in the
elderly)), merely discontinuing the administration of the drug
is thought to be sufficient to resolve minor bleeding in most
circumstances. [1, 5, 7, 8, 9]
2. direct factor Xa inhibitors
2.1. Rivaroxaban is approved in Europe and North
America for stroke prevention in nonvalvular AF and VTE
prophylaxis. It is a highly selective direct Factor Xa
inhibitor with oral bioavailability and rapid onset of action.
Rivaroxaban interrupts the intrinsic and extrinsic pathway
of the blood coagulation cascade, inhibiting both thrombin
formation and development of thrombi.  Rivaroxaban does
not inhibit thrombin and no effects on platelets have been
demonstrated. It also provides stable anticoagulation at a
fixed dose without the need for routine INR monitoring.
There is no specific reversal agent or antidote for
rivaroxaban, but its short half-life means that the
discontinuation of the drug is likely be adequate to correct
most bleeding problems caused by its use. [1, 5, 6, 7, 8, 9,
10]
2.2. Apixaban is a potent, reversible, highly
selective, direct inhibitor of free and prothrombinase-bound
factor Xa. It is characterized by > 50% oral bioavailability,
peak plasma concentrations 1-3 h after administration, and
a 12-h terminal half-life.
It is indicated in the prevention of venous
thromboembolism (VTE) after major orthopaedic surgery,
treatment of acute VTE, prevention of stroke or systemic
embolism in patients with atrial fibrillation and for
secondary prevention in ischemic heart disease.
It has low potential for drug-drug interactions and is
eliminated through mixed renal and metabolic pathways. [5,
7, 9, 11]
Tests for anticoagulation assesment
The prothrombin time ratio (PTR), defined as the
patient’s prothrombin time (PT) was used to monitor
anticoagulant therapy for many years.
Because of the variability of Prothrombin Time (PT)
values from different reagents, a system of standardizing the
reporting of anticoagulation activity has been developed by
the World Health Organization. [12, 13, 14]
In 1985, the International Committee on Thrombosis
and Homeostasis requested that all lots of thromboplastin
have an indication of their international sensitivity index
(ISI)which allows standardization of the results from
different laboratories by the introduction of the INR.
It is now widely used for monitoring anticoagulant
therapy and dosage planning. The INR for a healthy patient
is 1 and the therapeutic INR for those on anticoagulant
therapy typically ranges from 2 to 4, depending on the
reason for anticoagulation. [15, 16, 17, 18]
Both TT and ECT tests are the most sensitive tests
for quantifying the anticoagulant effects of dabigatran, but
in emergency situations, aPTT and/or TT, performed 6-12
hours prior surgery, would usually be the most accessible
methods for monitoring the anticoagulant effects of
dabigatran, because the ECT test (based on snake venom)
is not widely available. [9, 12]
FXaIs, rivaroxaban and apixaban, are reported to
slightly prolong PT and aPTT. The test that is reported to
be best able to monitor the anticoagulant effect of FXaIs (as
well as LMWH) is an anti–factor Xa assay; however, no
routine laboratory test monitoring of coagulation should be
required for patients receiving rivaroxaban or apixaban,
except possibly in special circumstances, such as renal
failure, obesity, or severely underweight patients. [1, 10]
Risk of thrombosis on stopping anticoagulation
therapy
In the past decade, it has become clear that routine
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procedures is not supported by the scientific literature, as it
may put patients at unnecessary medical risk for
thromboembolic events either from the cessation of
anticoagulant therapy or because of “rebound
phenomenon.”. This phenomenon is hypercoagulability
owing to increased thrombin production or platelet
activation if therapy is abruptly discontinued, which can
damaged prosthetic cardiac valves and even cause
thrombotic deaths in dental patients. So, unless serious
bleeding is anticipated, the therapy should be continued. [19]
The risk of thrombosis associated with temporarily
discontinuing anticoagulants prior to dental surgery is small
but potentially fatal. In the review of Wahl, 5/493 (1%)
patients undergoing 542 dental procedures and in whom
anticoagulants were withdrawn specifically for surgery, had
serious embolic complications of which four were fatal. The
four deaths comprised: a fatal cerebral embolism 17 days
after discontinuing warfarin; one fatal myocardial infarction
19 days after interruption of therapy for nine days; one fatal
cerebral thromboembolism five days postoperatively and
one patient died from a thromboembolism but no other data
are available. [20, 21]
Currently, most guidelines indicate that patients with
an INR less than 3.5 can undergo minor oral surgery (e.g.,
simple single extraction) without any adjustment in
anticoagulation. Withdrawal or temporary interruption of
anticoagulant medication, could lead to thromboembolic
events.  [12, 16, 20, 22]
Risk of bleeding complications with continuing
anticoagulant therapy
Specific consideration must be given to the issue of
whether oral anticoagulant treatment should be unaltered,
modified, or stopped according to possible bleeding
complications.
Hong C. et al. reported a study with 122 patients who
had a total of 240 dental extractions. 35 patients (29%) were
on concomitant medications thought to potentate bleeding.
Seven patients were on multiple antithrombotic medications
(excluding warfarin); 2 were taking a combination of aspirin,
cilastazol, and nonsteroidal analgesic medication; 3 were on
a combination of aspirin and clopidogrel; and 2 were on a
combination of aspirin and enoxaparin. Ten (8%) patients
had medical history which could potentially affect their risk
for bleeding.
The average INR value was 2.4 ±1.2. Multiple
extractions were performed in 41 cases. Local haemostatic
measures with gelatine compressed sponges and sutures were
used.
The results of this retrospective study suggest that the
overall prevalence of persistent bleeding after dental
procedures in patients on warfarin therapy is low (2%).
Additionally, most complications experienced were
controlled with local hemostatic measures. [16]
Pereira C. end al. conducted a study with 108
patients. 215 extractions were performed in which only one
case of postoperative bleeding occurred. Warfarin was used
by 98 patients; Warfarin associated with salicylic acetic acid
by 9 patients and salicylic acetic acid in only 1 patient. INR
ranged from 0.8 to 4.9, with a mean of 3.15. They concluded
that extractions in patients on oral anticoagulants must be
performed in the least traumatic manner possible. It is not
necessary to stop anticoagulant therapy prior teeth
extractions. Local hemostasis techniques, such as sutures
alone are sufficient to prevent hemorrhagic complications.
[23]
Perini et al. published a study with 400 patients that
have been treated with warfarin for at least six months
submitted to dental extractions without modifying the
anticoagulant therapy. All patients have been treated with
suture, positioning of oxidized cellulose and topic
tranexamic acid. The level of INR appraised immediately
before surgery, ranged from 1.8 to 4. There were 7 cases of
late bleeding which have been treated with socket toilette
and a new suture, in no case more than local hemostatic
measures were needed. [24]
Sacco R. end al. presented a study with 131 patients
on OAT which were randomized to reduced anticoagulation
or to full anticoagulation. 511 teeth were extracted by the
same surgeon. Mild bleeding, but excessive enough to
warrant adoption of supplementary local haemostatic
measures, was observed in 10 cases (15.1%) in the reduced
dosage group and in 6 cases (9.2%) in the unmodified
dosage group, which wasn’t significant difference. This
randomized study shows that, using simple measures for
local haemostasis, it is not necessary to reduce OAT in
patients undergoing routine dental extractions. 25
Salam S. et al. presented a study of 150
anticoagulated patients who required extraction of at least
one tooth. The INR ranged from 0.9 to 4.2. All sockets were
subsequently packed with absorbable oxycellulose and
sutured.
Ten patients (7%) bled after extraction, enough to
require a return to hospital.
Five patients of 101 with an INR ≤ 2.5, and 5 with
an INR > 2.5 out of 49 bled after extraction. All patients
who bled were managed conservatively and none was
admitted to hospital.
The authors concluded that the risk of thrombo-
embolism outweighed the risk of postoperative bleeding and
patients whose INR is up to 4.0 do not have clinically
significant bleeds post-operatively. [26, 27]
Sanz M. et al. investigated INR level in patients on
warfarin therapy. They concluded that most of the
anticoagulated patients do not have INR within the
therapeutic range when attending a dental practice, which
might increase the risk of bleeding or a thromboembolic
event as a consequence of the dental intervention. INR324 http://www.journal-imab-bg.org / J of IMAB. 2013, vol. 19, issue 4/
testing should, therefore, be incorporated into any dental
practice in which invasive procedures are performed. [6, 28]
Local haemostasis
French Association of Oral Surgery and Medicine
does not recommend the use of block anaesthetic techniques,
including Inferior alveolar nerve block, in patients taking
oral anticoagulants, whereas the British Committee for
Standards in Haematology mentions the safety of inferior
alveolar nerve block only if the INR is less than 3. Without
doubt it is advisable to use intraligamentary or intraseptal
techniques of local anaesthesia in these patients, as they are
safer and less likely to provoke haemorrhagic complications.
[13, 29, 30, 31]
Local haemostasis after single or multiple teeth
extractions can be achieved through: - - Local pressure
(biting on gauze); site packing with gelatine sponges;
absorbable oxycellulose; microcrystalline; collagen;
additional suturing; Electrocauterization;  topical
thrombin powder.
- Fibrin sealants induce clot formation at the site of
the surgical wound. It mimics the last phase of blood clotting
by conversion of fibrinogen to fibrin. The system has 2
components. The first consists mainly of fibrinogen and
plasma proteins, and the second consists of thrombin and
calcium chloride. When the 2 components are mixed,
thrombin converts fibrinogen into fibrin so that clotting is
initiated and the mixture is solidified. Fibrin sealants for oral
surgery in patients on oral anticoagulant therapy can be used
to reduce postoperative haemorrhage in the therapeutic INR
range of 1 to 5 in patients with a wide range of degrees of
surgical trauma. [12, 13, 15, 32]
- 5% tranexamic acid mouthwashes used 4 times a
day for 2 days (10ml in mouth for 2min) was reported to
be effective in patients on anticoagulant therapy. This
treatment modality is an attempt to reduce the amount of
lysed fibrin and consequently the incidence of postoperative
bleeding. It is conceivable that the mouthwash may have an
effect only on the superficial clot and not on bleeding from
the depth of the socket, an area not accessible to the
mouthwash. [15, 29, 32]
Pain control
Generally paracetamol is considered a safe analgesic
drug for patients taking anticoagulant medications and it may
be taken in normal doses if pain control is needed and no
contraindication exists.
Recommendations of the British Committee for
Standards in Haematology: Patients taking warfarin should
not be prescribed nonselective NSAIDs as analgesics
following dental surgery. These drugs inhibit platelet
aggregation and may cause GI bleeding and peptic ulceration
and/or perforation. Increased bleeding may occur during
concomitant NSAID therapy with warfarin independently of
an increase in INR. [20, 22]
Patients taking Acenocoumarol should not be
prescribed nonselective NSAIDs as analgesics following
dental surgery, which potentate bleeding. [4, 5]
 Association of new oral anticoagulants with other
anticoagulants, platelet inhibitors
(Aspirin, Clopidogrel, Ticlodipine, Prasugrel,
Ticagrelor, and others), and non-steroidal anti-inflammatory
drugs (NSAID) increases the bleeding risk. [34]
COX-2 inhibitors are unlikely to increase bleeding
time following invasive dental procedures, although there
are no prospective studies in humans. [18]
Interactions with drugs frequently used or
prescribed in dentistry
Macrolide antibiotics (i.e., erythromycin, clarithro-
mycin,  and possibly azithromycin) and sulphonamides have
been implicated in causing significant episodes of bleeding
in patients taking warfarin or acenocoumarol. [4, 5]
Other drugs that may enhance the hypoprothrom-
binemic effect of anticoagulant drugs include tetracyclines
(especially doxycycline or tetracycline), and in particular the
second and third generation cephalosporins, and
levofloxacin. Postulated mechanisms include an antibiotic-
induced reduction in prothrombin activity
(hypoprothrombinemia) and a reduction in gastrointestinal
bacteria flora essential for vitamin K production which is
subsequently used to produce various clotting factors. [18]
Dabigatran and rivaroxaban are reported to have
comparatively few drug-drug interactions.
The concomitant use of systemic azoleantimycotics
(ketoconazole, itraconazole, voriconazole, and
posaconazole) as well as HIV protease inhibitors is not
recommended in patients being treated with rivaroxaban.
Fluconazole is expected to have less effect on
rivaroxaban exposure and can be coadministered with
caution.
Although platelet aggregation was reported to be
unaffected, concomitant use of some NSAIDs and
rivaroxaban significantly increased bleeding time compared
with rivaroxaban alone. [1, 14]
CONCLUSIONS
INR values should be obtained within 24 hours before
the dental procedure. For patients with  INR in the
therapeutic range 2-4 or below, therapy need not be modified
or discontinued for simple single dental extractions. More
complicated and invasive oral surgical procedures for
patients with an INR on the high end of the scale or greater
than 3.5  should be referred to physician for dose adjustment
or therapy alteration before invasive dental procedures. [13,
16, 28]
The risk of bleeding may be minimised by: use of
oxidised cellulose or collagen sponges, fibrin sealants and
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days.
Co morbid conditions as liver disease, bone marrow
disorders, biliary tract obstruction, malabsorption, renal
disease, and cancers such as leukaemia may potentate an
existing bleeding problem. Increased inflammation of the
oral tissues in patients on OAT can contribute to excessive
bleeding even with minor procedures.
These patients should NOT have a surgical dental
procedure and should be referred to a dental hospital or
hospital-based oral and maxillofacial surgery department.
The use of concomitant medications, including
antibiotics, antifungals, nonsteroidal anti-inflammatory drugs
(NSAIDs), and other platelet aggregation inhibitors  may
affect a patient’s ability to achieve adequate haemostasis
after a routine dental procedure.
For patients being treated with one of these new oral
anticoagulants, the amount of “real-world” data and
experience regarding the management of patients undergoing
dental procedures that are likely to involve significant
bleeding is currently lacking.
Clearly, clinical studies are needed to determine the
effects that the new oral DTIs and FXaIs have on bleeding
and haemostasis after tooth extractions and other surgical
dental procedures.
At this time patients taking dabigatran, rivaroxaban
or apixaban should be consulted with the treating physician
prior dental surgical procedures. [1]
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